Author:
Watabe Tadashi,Ikeda Hayato,Nagamori Shushi,Wiriyasermkul Pattama,Tanaka Yoko,Naka Sadahiro,Kanai Yasukazu,Hagiwara Kohei,Aoki Masanao,Shimosegawa Eku,Kanai Yoshikatsu,Hatazawa Jun
Funder
KAKENHI Grant-in-Aid for Scientific Research
Publisher
Springer Science and Business Media LLC
Subject
Radiology Nuclear Medicine and imaging,General Medicine,Radiology Nuclear Medicine and imaging,General Medicine
Reference32 articles.
1. Imahori Y, Ueda S, Ohmori Y, Kusuki T, Ono K, Fujii R, et al. Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma. J Nucl Med. 1998;39(2):325–33.
2. Pisarev MA, Dagrosa MA, Juvenal GJ. Boron neutron capture therapy in cancer: past, present and future. Arq Bras Endocrinol Metabol. 2007;51(5):852–6.
3. Wongthai P, Hagiwara K, Miyoshi Y, Wiriyasermkul P, Wei L, Ohgaki R, et al. Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2. Cancer Sci. 2015;106(3):279–86.
4. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 1998;273(37):23629–32.
5. Shimizu A, Kaira K, Kato M, Yasuda M, Takahashi A, Tominaga H, et al. Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in cutaneous melanoma. Melanoma Res. 2015;25(5):399–405.
Cited by
55 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献